Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Free Cash Flow (2020 - 2025)

Foghorn Therapeutics has reported Free Cash Flow over the past 6 years, most recently at -$22.3 million for Q4 2025.

  • Quarterly results put Free Cash Flow at -$22.3 million for Q4 2025, up 11.4% from a year ago — trailing twelve months through Dec 2025 was -$86.1 million (up 14.97% YoY), and the annual figure for FY2025 was -$86.1 million, up 14.97%.
  • Free Cash Flow for Q4 2025 was -$22.3 million at Foghorn Therapeutics, down from -$18.9 million in the prior quarter.
  • Over the last five years, Free Cash Flow for FHTX hit a ceiling of $271.3 million in Q1 2022 and a floor of -$32.0 million in Q2 2023.
  • Median Free Cash Flow over the past 5 years was -$24.1 million (2021), compared with a mean of -$8.3 million.
  • Biggest five-year swings in Free Cash Flow: tumbled 626.67% in 2021 and later skyrocketed 1225.43% in 2022.
  • Foghorn Therapeutics' Free Cash Flow stood at $11.8 million in 2021, then crashed by 344.7% to -$28.9 million in 2022, then rose by 4.72% to -$27.5 million in 2023, then increased by 8.66% to -$25.1 million in 2024, then rose by 11.4% to -$22.3 million in 2025.
  • The last three reported values for Free Cash Flow were -$22.3 million (Q4 2025), -$18.9 million (Q3 2025), and -$21.0 million (Q2 2025) per Business Quant data.